These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6321203)

  • 1. Effect of beta-FNA on opiate receptor binding: preliminary evidence for two types of mu receptors.
    Rothman RB; Bowen WD; Schumacher UK; Pert CB
    Eur J Pharmacol; 1983 Nov; 95(1-2):147-8. PubMed ID: 6321203
    [No Abstract]   [Full Text] [Related]  

  • 2. 5-Methylated naloxone, naltrexone, oxymorphone, and their 14-O-methyl ethers.
    Schmidhammer H; Leander JD; Mayer-Valkanover K; Nussbaumer C; Schmidt C; Schoepp DD; Schratz A; Walla-Kugler M
    Prog Clin Biol Res; 1990; 328():41-4. PubMed ID: 2154800
    [No Abstract]   [Full Text] [Related]  

  • 3. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.
    Hahn EF; Nishimura S; Goodman RR; Pasternak GW
    J Pharmacol Exp Ther; 1985 Dec; 235(3):839-45. PubMed ID: 2416909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of a new opiate antagonist, nalmefene, to rat brain membranes.
    Michel ME; Bolger G; Weissman BA
    Methods Find Exp Clin Pharmacol; 1985 Apr; 7(4):175-7. PubMed ID: 2991678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of beta-FNA on opiate delta receptor binding.
    Rothman RB; Schumacher UK; Pert CB
    J Neurochem; 1984 Oct; 43(4):1197-200. PubMed ID: 6088697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naltrexone-induced opiate receptor supersensitivity.
    Zukin RS; Sugarman JR; Fitz-Syage ML; Gardner EL; Zukin SR; Gintzler AR
    Brain Res; 1982 Aug; 245(2):285-92. PubMed ID: 6289965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid receptor binding characteristics of the non-equilibrium mu antagonist, beta-funaltrexamine (beta-FNA).
    Ward SJ; Fries DS; Larson DL; Portoghese PS; Takemori AE
    Eur J Pharmacol; 1985 Jan; 107(3):323-30. PubMed ID: 2984010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.
    Rothman RB; Bykov V; Mahboubi A; Long JB; Jiang Q; Porreca F; de Costa BR; Jacobson AE; Rice KC; Holaday JW
    Synapse; 1991 Jun; 8(2):86-99. PubMed ID: 1652797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 10-Ketonaltrexone and 10-ketooxymorphone.
    Archer S; Seyed-Mozaffari A; Ward S; Kosterlitz HW; Paterson SJ; McKnight AT; Corbett AD
    J Med Chem; 1985 Jul; 28(7):974-6. PubMed ID: 2409281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of an irreversible opiate antagonist (beta-FNA, beta-funal-trexamine) to demonstrate dynorphin selectivity for K-opioid sites.
    Huidobro-Toro JP; Yoshimura K; Way EL
    Life Sci; 1982 Nov; 31(22):2409-16. PubMed ID: 6130451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment.
    Tempel A; Zukin RS; Gardner EL
    Life Sci; 1982 Sep 20-27; 31(12-13):1401-4. PubMed ID: 6292636
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic naltrexone increases opiate binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat.
    Bardo MT; Bhatnagar RK; Gebhart GF
    Brain Res; 1983 Dec; 289(1-2):223-34. PubMed ID: 6318895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
    Liu-Chen LY; Yang HH; Li S; Adams JU
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines.
    Hahn EF; Carroll-Buatti M; Pasternak GW
    J Neurosci; 1982 May; 2(5):572-6. PubMed ID: 6176696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone.
    Takemori AE; Larson DL; Portoghese PS
    Eur J Pharmacol; 1981 Apr; 70(4):445-51. PubMed ID: 6263637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.
    Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW
    J Pharmacol Exp Ther; 1988 Nov; 247(2):405-16. PubMed ID: 2846819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of beta-funaltrexamine on radiolabeled opioid binding.
    Recht LD; Pasternak GW
    Eur J Pharmacol; 1987 Aug; 140(2):209-14. PubMed ID: 2822439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
    Tam SW; Liu-Chen LY
    J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diastereomeric 6-desoxy-6-spiro-alpha-methylene-gamma-butyrolactone derivatives of naltrexone and oxymorphone. Selective irreversible inhibition of naltrexone binding in an opioid receptor preparation by a conformationally restricted michael acceptor ligand.
    Koolpe GA; Nelson WL; Gioannini TL; Angel L; Simon EJ
    J Med Chem; 1984 Dec; 27(12):1718-23. PubMed ID: 6209395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intracerebroventricular beta-funaltrexamine on mu and delta opioid receptors in the rat: dichotomy between binding and antinociception.
    Liu-Chen LY; Li SX; Wheeler-Aceto H; Cowan A
    Eur J Pharmacol; 1991 Oct; 203(2):195-202. PubMed ID: 1666046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.